WAT's fourth-quarter 2024 results reflect strong pharma growth and robust gains across all regions. However, forex headwinds hurt.

ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.

CBRE's Q4 results reflect a year-over-year rise in revenues due to solid performances by all business segments despite the challenging macro...

IRM's Q4 results reflect solid performance in all business segments but are marred by higher interest expenses year over year.

GRMN's fourth-quarter 2024 results reflect solid momentum across Outdoor, Fitness, Aviation, Marine and Auto OEM segments.

DUK's fourth-quarter 2024 earnings beat estimates, and revenues increase year over year.

AVNT's fourth-quarter organic sales rise 5% year over year aided by growth in all geographic regions.

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year...

COOP's fourth-quarter 2024 results benefit from solid growth in the Servicing and Originations segments. A rise in expenses acts as a spoilsport.

WMT's fiscal Q4 results reflect increased sales and earnings growth across all segments. Management announced an annual dividend hike.